medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2016, Number 5

Next >>

Rev Invest Clin 2016; 68 (5)

Invasive and Complicated Pneumococcal Infection in Patients with Cancer

Zarco-Márquez S, Volkow-Fernández P, Velázquez-Acosta C, Echániz-Avilés G, Carnalla-Barajas MN, Soto-Noguerón A, Cornejo-Juárez P

Language: English
References: 16
Page: 221-228
PDF size: 112.58 Kb.


ABSTRACT

Background: In susceptible patients, Streptococcus pneumoniae can cause complicated pneumonia and invasive pneumococcal disease. The aim of this study was to assess the clinical and antimicrobial features of complicated and invasive pneumococcal disease in patients with cancer. Methods: We conducted a retrospective study including all S. pneumoniae isolates between January 1, 2007 and December 31, 2015 in an oncology center. Capsular serotyping was done in isolates from sterile sites. Results: There were 103 episodes: 69 with invasive pneumococcal disease and 34 with complicated pneumonia. Sixty-two patients were male (60%); mean age was 50 years. Eighty-four isolates were susceptible to penicillin (81.6%), 11 (10%) were intermediate, and eight (8.3%) were resistant. Serotyping was performed in 64 isolates; the main serotypes identified were 3 (n = 13) and 19A (n = 11). No patient had a record of vaccination. Mortality at seven days attributed to pneumococcal infection was different in invasive pneumococcal disease (n = 18, 28.6%) vs. pneumonia (n = 3, 8.9%; p = 0.04). Thirty-day mortality related with the infectious process was statistically different between both groups: 21 patients with invasive pneumococcal disease (30.4%) and six with pneumonia (17.6%; p = 0.04). By logistic analysis, the risk factor associated with mortality was not having received appropriate antimicrobial treatment in the first 48 hours. Conclusions: S. pneumoniae is a pathogen related with high mortality in patients with cancer. Pneumococcal immunization needs to be reinforced in this population.


REFERENCES

  1. Shigayeva A, Rudnick W, Green K, et al; Toronto Invasive Bacterial Diseases Network. Invasive pneumococcal disease among immunocompromised persons: Implications for vaccination programs. Clin Infect Dis. 2016;62:139-47.

  2. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ; The SPAT Group. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect. 2010; 138:1804-10.

  3. G arcía-Vidal C, Ardanuy C, Gudiol C, et al. Clinical and microbiology epidemiology of Streptococcus pneumoniae bacteremia in cancer patients. J Infect. 2012;65:521-7.

  4. L in SH, Liao WH, Lai CC, et al. Comparison of clinical features, antimicrobial susceptibility, serotype distribution and outcomes of patients with hospital- and community-associated invasive pneumococcal disease. Int J Antimicrob Agents. 2010; 36:119-23.

  5. Youssef S, Rodríguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients. Medicine. 2007;86:69-77.

  6. Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing; 26th Informational Supplement, 2015. Approved Standard M100-S26. Wayne, PA, USA: Clinical and Laboratory Standards Institute.

  7. Ikegame S, Wakamatsu K, Kumazoe H, et al. A retrospective analysis of 111 cases of pneumococcal pneumonia: clinical features and prognostic factors. Intern Med. 2012;51:37-43.

  8. Christensen JS, Jensen TG , Kolmos HJ, Pedersen C, Lassen A. Bacteremia with Streptococcus pneumoniae: sepsis and other risk factors for 30-day mortality--A hospital-based cohort study. Eur J Clin Microbiol Infect Dis. 2012;31:2719-25.

  9. Marrie TJ, Tyrrell GJ, Garg S, Vanderkooi OG. Factors predicting mortality in invasive pneumococcal disease in adults in Alberta. Medicine. 2011;90:171-9.

  10. Bouza E, Pintado V, Rivera S, et al. Nosocomial bloodstream infections caused by Streptococcus pneumoniae. Clin Microbiol Infect. 2015;11:919-24.

  11. E chániz-Avilés G, San Román-Álvarez L, Sánchez-Alemán M, Carnalla- Barajas MN, Soto-Noguerón A. Prevalence of Streptococcus pneumoniae serotype 19A before and after the introduction of the heptavalent conjugate vaccine in Mexico. Salud Publica Mex. 2014;56:266-71.

  12. G eng Q, Zhang T, Ding Y, et al. Molecular characterization and antimicrobial susceptibility of Streptococcus pneumoniae isolated from children hospitalized with respiratory infections in Suzhou, China. PLoS One. 2014;9:e93752.

  13. A rdanuy C, Marimón JM, Calatayud L, et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007- 2009): implications for future vaccination strategies. PLoS One. 2012;7:e43619.

  14. Rubin LG , Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309-18.

  15. SIREVA Network 2013. [Data for country and age groups about Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitides strains characteristics in invasive diseases]. Spanish. Washington, D.C., USA: World Health Organization; 2013. ISBN 978-92-75-31918-5. http://iris.paho.org/xmlui/ handle/123456789/31147.

  16. T omic V, Dowzicky MJ. Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008). Ann Clin Microbiol Antimicrob. 2014;13:52.




2020     |     www.medigraphic.com